In vitro sensitisation testing strategy

Method Description

In vitro STS describes the use of a testing strategy based on existing methods that has a sufficient predictive capacity to be used as a stand-alone method for sensitisation testing. It addresses the first three key events (KE) of the of the skin sensitization Adverse Outcome Pathway (AOP).

These key events are measured by formally validated and peer-reviewed methods, i.e. KE1 protein binding: DPRA (OECD TG 442C), KE2 keratinocyte activation: KeratinosensTM (OECD TG 442D), LuSens (ESAC reviewed) and KE3 dentritic cell activation: h-CLAT (OECD TG 442E), MUSST (ESAC reviewed). These methods constitute the main components of the testing strategy.